Sandbox Reserved 191: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
=Inhibitors of PPT-1= | =Inhibitors of PPT-1= | ||
'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme, which has a serine [[lipase]] consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride [https://en.wikipedia.org/wiki/PMSF (PMSF)], a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to | '''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme, which has a serine [[lipase]] consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride [https://en.wikipedia.org/wiki/PMSF (PMSF)], a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to <scene name='58/580839/Basic-hdsf-nosurface/4'> bind and inhibit PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT-1. The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1<ref name="INCL">PMID:10801859</ref> | ||
=Diseases Associated With PPT-1= | =Diseases Associated With PPT-1= | ||
[[Image:All_mutations.jpg|200px|right|thumb|Figure 3: Mutations to PPT-1 associated with INCL. Twelve mutations of INCL are shown in the white on the blue PPT-1 protein.]] | [[Image:All_mutations.jpg|200px|right|thumb|Figure 3: Mutations to PPT-1 associated with INCL. Twelve common mutations of INCL are shown in the white on the blue PPT-1 protein.]] | ||
[https://en.wikipedia.org/wiki/Infantile_neuronal_ceroid_lipofuscinosis Infantile neuronal ceroid lipofuscinosis (INCL)] is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations in PPT-1. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL | [https://en.wikipedia.org/wiki/Infantile_neuronal_ceroid_lipofuscinosis Infantile neuronal ceroid lipofuscinosis (INCL)] is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations in PPT-1. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL <ref name="mutations" />. | ||
[[Image:Thr-_mut.png|200px|left|thumb|Figure 4: Common Mutation associated with JNCL and LINCL involve mutations far away from the active Ser-115. ]] | [[Image:Thr-_mut.png|200px|left|thumb|Figure 4: Common Mutation associated with JNCL and LINCL involve mutations far away from the active Ser-115. ]] | ||
Juvenile NCL (JNCL) and Late-Infantile NCL (LINCL) are less severe forms of INCL in which onset of symptoms occur much later in life; between the ages of 30-40. A possible explanation for the later onset of symptoms could be that the mutations associated with JNCL and LINCL occur away from the active site of PPT-1. Since the mutation does not affect the active site this results in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75, an amino acid located on the alpha-1 helix of PPT-1 (Figure 4). The Thr-75 amino acid is located 20.6Å away from the active site of PPT-1 which indicates that Thr-75 plays no role in the catalytic activity of the catalytic triad | Juvenile NCL (JNCL) and Late-Infantile NCL (LINCL) are less severe forms of INCL in which onset of symptoms occur much later in life; between the ages of 30-40. A possible explanation for the later onset of symptoms could be that the mutations associated with JNCL and LINCL occur away from the active site of PPT-1. Since the mutation does not affect the active site this results in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75, an amino acid located on the alpha-1 helix of PPT-1 (Figure 4). The Thr-75 amino acid is located 20.6Å away from the active site of PPT-1 which indicates that Thr-75 plays no role in the catalytic activity of the catalytic triad | ||
<ref name="mutations" /> | <ref name="mutations" />. | ||
In both JNCL and LINCL, the activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way to potentially increase the activity of mutant PPT-1 variants is to use [https://en.wikipedia.org/wiki/Protein_chaperones protein chaperones] that help refold PPT-1 in the [http://en.wikipedia.org/wiki/Endoplasmic_reticulum endoplasmic reticulum]. Although this is not a cure for INCL, increasing the activity of PPT-1 by only '''ABC'''-fold can also increase the life expectancy for individuals with INCL <ref name="Kelly-1">PMID:20346914</ref>. | |||
Despite the life-threatening diseases associated with decreased PPT-1 activity, inhibition of PPT-1 has also been | Despite the life-threatening diseases associated with decreased PPT-1 activity, inhibition of PPT-1 has also been shown to be a potential cancer target. Proteins involved in signaling and growth are post-translationally modified with palmitic acid. PPT-1 is involved with removing palmitate from lipid-modified proteins and this [http://en.wikipedia.org/wiki/Palmitoylation palmitoylation] is necessary for membrane association. When PPT-1 is over expressed, cells become protected from cell death, which leads to tumor formation. PPT-1 inhibition in cultured tumor cells led to selective tumor cell death. <ref name="Kelly-1" /> | ||
== Mutations in Palmitoyl Protein Thiosterase 1== | == Mutations in Palmitoyl Protein Thiosterase 1== | ||
Revision as of 17:14, 24 April 2014
| This Sandbox is Reserved from Feb 02, 2011, through Jul 31, 2011 for use by the Biochemistry II class at the Butler University at Indianapolis, IN USA taught by R. Jeremy Johnson. This reservation includes Sandbox Reserved 191 through Sandbox Reserved 200. |
To get started:
More help: Help:Editing |
| ||||||||||||
References
External Resources
[1] Wikipedia page on Gauche Effect
[2] Wikipedia page on palmitic acid.
[3] Wikipedia page on Infantile neuronal ceroid lipofuscinosis
[4] Wikipedia page on PMSF
[5] Wikipedia page on Protein Chaperones
[6] Wikipedia page on Endoplasmic reticulum
[7] Wikipedia page on Palmitoylation
[8] Page on Late Infantile neuronal ceroid lipofuscinosis
[9] Page on Juvenile neuronal ceroid lipofuscinosis


